The Fort Myers, Fla.-based company plans to offer 13.3 million shares of common stock at $14 to $16 per share. 21st Century Oncology will also offer 1.5 million shares of preferred stock at $50 per share. Morgan Stanley, J.P. Morgan and Wells Fargo are the book-running managers for the IPO.
21st Century Oncology operates 185 treatment centers, specializing in radiation oncology and other medical specialty services. Daniel Dosoretz, MD, a radiation oncologist, co-founded the company and serves as its CEO.
More Articles on Healthcare and IPOs:
10 Things To Know About Castlight Health’s IPO
IMS Health’s $1.3B IPO Shows Investors Recognize Value of Big Data
Imprivata Files $115M IPO
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
